Why age and activity shift the decision

For a younger or active patient weighing these options, the practical question is not which procedure sounds more advanced — it is which one leaves the most doors open. Total knee replacement (TKR) is a highly effective operation, but for someone in their thirties or forties, the arithmetic of implant longevity is genuinely difficult. Published survivorship data show that in patients under 55, all-cause TKR survival ranges from around 90–99% at ten years but falls to roughly 52–65% at 40 years — a timeline that is well within reach for someone having the operation at 40.

The revision burden matters even before that endpoint arrives. Patients under 50 face up to a 35% lifetime risk of needing a further operation on the same knee; young males carry roughly four to five times the lifetime revision probability of patients aged over 70. Revision surgery is substantially more complex and carries higher complication rates than a primary procedure, so every year the original joint can be preserved in a functioning state represents a real clinical advantage.

Activity restrictions after TKR are a permanent feature of life with an implant, not a temporary phase of recovery. Running, jumping, and pivoting sports are strongly discouraged to reduce wear on the bearing surfaces — a lasting trade-off for patients whose identity and wellbeing are tied to sport or physical work. NHS guidance reflects this: most total knee replacements are carried out on people aged 60–80, and the NHS explicitly cautions that younger, physically active patients are more likely to wear the joint out prematurely.

Cartilage repair outcomes, meanwhile, are demonstrably better in patients under 40 — a window that argues for acting on focal defects early, while the biological conditions for successful repair are most favourable. The rest of this article uses two primary guides — defect size and the overall condition of the knee — to map which repair option fits which presentation, and where replacement becomes the more realistic choice.

How defect size guides technique choice

Technique selection in cartilage repair turns first on a practical question: how large is the defect, and how deep does the damage go? That single measurement — lesion area on MRI, confirmed at the time of assessment — does more to determine the right procedure than symptoms alone ever can.

The repair options sit along a size ladder. For isolated, full-thickness defects under roughly 2 cm² (ICRS Grade III–IV, with healthy surrounding cartilage and intact subchondral bone), single-stage autograft procedures such as OATS or mosaicplasty are well established — transferring a small plug of healthy bone and cartilage from a low-load area of the patient's own knee to fill the defect. These carry solid short-to-mid-term outcomes and avoid the two-stage process required by cell-based techniques.

The 2–10 cm² window is where matrix-based and cell-based repair comes into its own. The SUMMIT trial compared MACI directly against microfracture for defects of 3 cm² or larger, finding significantly better KOOS pain and function scores at both two and five years in favour of MACI — the strongest head-to-head evidence currently available in this size range. ACI remains an established alternative with long-term data behind it.

Above 10 cm², or where bone loss accompanies the cartilage damage, fresh osteochondral allograft (OCA) becomes the primary surgical option. For contained focal presentations, published series report five-year survivorship in the region of 80–88%, though this falls to around 59% at 15 years when bipolar or very large lesions are involved.

Defect depth is equally important: bone involvement changes both the technique used and the recovery expected. Placing a patient accurately on this ladder requires a consultant assessment and MRI — including cartilage mapping where available — rather than symptom severity alone.

Cartilage repair in practice: from outpatient scaffolds to osteochondral grafts

Microfracture sits at the base of the repair ladder historically, but its clinical standing has declined considerably. The tissue it creates — fibrocartilage — is mechanically weaker than native hyaline cartilage and tends to degrade within two to three years. There is a compounding problem: the drilling penetrates the subchondral bone plate, and damage to that layer can complicate or foreclose subsequent repair attempts. Most specialist practice now treats microfracture as a historical reference point rather than a modern first choice, particularly for active patients in whom long-term durability is the priority.

At the least-invasive end of the current options is the ChondroFiller injection — an injectable acellular collagen scaffold placed under ultrasound guidance as an outpatient procedure, without general anaesthesia or a theatre setting. The mechanism is matrix-induced chondrogenesis: the scaffold is delivered into the focal defect and recruits the patient's own progenitor cells to initiate repair tissue formation. Published knee series report meaningful improvements in IKDC function scores and cartilage fill on MRI (MOCART), with a low complaint rate. For patients with eligible focal defects who cannot or prefer not to undergo theatre-based surgery, this pathway represents a practical, evidence-supported option at the regenerative end of the non-surgical spectrum.

AMIC (autologous matrix-induced chondrogenesis) bridges the gap between marrow stimulation and cell-based repair in a single theatre procedure, combining marrow stimulation with a collagen scaffold to guide repair tissue quality. It is generally considered for defects in the 2–4 cm² range and avoids the two-stage process of cell-based techniques.

OATS and mosaicplasty transfer osteochondral plugs from a low-load area of the patient's own knee. The approach is single-stage and suited to defects up to approximately 4 cm². Ten-year data from Gudas and colleagues demonstrated a sustained functional advantage over microfracture. Donor-site morbidity is a meaningful consideration that warrants open discussion before surgery: the harvest site becomes a secondary defect, and in some patients this causes its own symptoms.

MACI and ACI carry the strongest evidence for the 2–10 cm² range — the SUMMIT trial data providing the benchmark, as outlined above. Both remain two-stage, resource-intensive procedures. An emerging single-stage variant (sometimes called STACI or next-generation ACI; Taylor & Lee, 2019) aims to collapse cell harvest and implantation into a single procedure, but its evidence base is limited compared with established two-stage approaches and should be considered an evolving option rather than a validated alternative.

When alignment needs correcting before repair can work

Before any cartilage repair technique can be expected to work, one structural question must be answered: is the knee loading the damaged compartment normally? If not, even a technically sound repair will be placed under abnormal mechanical stress and is likely to fail prematurely — regardless of which procedure is chosen.

Varus deformity (bow-legged alignment) drives load into the medial compartment; valgus deformity (knock-kneed alignment) does the same to the lateral. Where malalignment is contributing to cartilage damage, an osteotomy — high tibial osteotomy (HTO) for varus, distal femoral osteotomy (DFO) for valgus — is typically required to redistribute load before or alongside repair. In published series combining HTO with marrow stimulation in varus knees, second-look arthroscopy at two years showed approximately 85% cartilage regeneration on the femoral condyle, illustrating how dramatically a corrected mechanical environment can support the repair process.

Osteotomy can be performed at the same sitting as the cartilage procedure or staged separately, depending on defect size and overall joint condition. The important framing is that osteotomy is an enabling step — it creates the conditions in which repair can succeed — not an alternative to it.

For younger patients with isolated medial compartment OA rather than a focal defect, osteotomy alone can be joint-preserving. However, formal cost-effectiveness modelling indicates that in patients of around 45 years with medial OA, HTO is economically dominated by unicompartmental knee arthroplasty (UKA) — producing fewer quality-adjusted life months at higher cost — so the decision requires careful individual assessment.

When knee replacement becomes the right answer

Preservation works best when there is cartilage worth preserving. Diffuse, pan-compartmental degeneration — where damage has spread across multiple joint surfaces — falls outside the scope of any repair technique, and here replacement is appropriate regardless of age. What matters is recognising that point clearly rather than delaying an inevitable decision.

For patients whose OA remains confined to the medial compartment, unicompartmental knee replacement (UKR) is a genuine middle-ground option that many active patients do not know exists. A retrospective study of 119 knees in patients aged 60 or below found cemented mobile-bearing medial UKR achieved 86.7% implant survival at 15 years, with 96% of patients exceeding the threshold for a satisfactory Oxford Knee Score at mean 16-year follow-up. The procedure preserves the ACL and resects far less bone than total replacement — factors that keep future revision options open. Formal economic modelling places UKR as the most cost-effective strategy for medial compartment OA in patients of around 45 years, outperforming TKA on quality-adjusted outcomes. In selected patients who also have coexisting ACL deficiency, single-stage UKR combined with ACL reconstruction produced 100% return to sport at five-year follow-up with no revision procedures in published series — a finding that challenges the assumption that any form of knee replacement ends active sport.

Total knee arthroplasty (TKA) is appropriate when disease spans multiple compartments and no preservation route remains realistic. Ten-year survivorship in patients under 55 runs from 90.6% to 99%, but falls to 52–65% at 40 years — which is why implant longevity is the dominant concern for younger patients. The high-impact activity limitations that accompany TKA (outlined in the opening section) form part of that long-term trade-off; for patients with severe, widespread disease, relief from persistent pain often justifies accepting them.

OCA transplantation provides a meaningful bridge when primary cartilage repair fails: five-year survival in this salvage setting runs 79–87.8%, meaning a failed initial procedure does not automatically trigger immediate replacement. The pathway from repair through OCA salvage to arthroplasty is deliberate and mapped — not a sequence of setbacks.

Getting the right assessment at Lincolnshire Knee

The decision tree covered in the preceding sections — lesion size, alignment, tissue depth, age, and activity goals — only translates into a clear recommendation when it is fed accurate data. For a patient in their late thirties with a 4 cm² femoral condyle lesion, the practical question is whether surrounding cartilage remains intact, whether the subchondral bone is healthy, and whether compartment loading is even. Those variables determine whether MACI, osteotomy-plus-repair, or unicompartmental replacement is the appropriate next step — and they cannot be resolved from a symptom checklist or a standard X-ray alone.

At Lincolnshire Knee, that workup includes onMRI™ AI-driven cartilage mapping — providing T2 mapping and defect segmentation to characterise lesion grade and surrounding tissue quality — alongside MAI Motion® biomechanical assessment, which identifies gait asymmetries and compartment loading patterns relevant to alignment decisions. Together these tools produce a clinical picture specific to that patient's anatomy and goals rather than a generic protocol.

Lincolnshire Knee accepts patients without GP referral, with assessments available at Sleaford NG34 (head office, Open MRI, and Regeneration Hub) and Grantham NG31. To arrange a structured knee assessment, visit lincolnshireknee.co.uk.

1. [1] Osteochondral Allograft Transplantation as a Salvage Procedure After Failed Index Cartilage Surgery of the Knee: A Systematic Review. (2025). https://doi.org/10.1177/03635465241238466 https://doi.org/10.1177/03635465241238466
2. [2] Autologous minced cartilage repair for chondral and osteochondral lesions of the knee: good outcomes and low reoperation rates at minimum five-year follow-up. (2023). https://doi.org/10.1007/s00167-023-07546-1 https://doi.org/10.1007/s00167-023-07546-1
3. [3] Excellent outcomes with combined single-stage medial unicompartment knee replacement and ACL reconstruction in young, active patients. (2022). https://doi.org/10.1016/j.knee.2022.04.008 https://doi.org/10.1016/j.knee.2022.04.008
4. [4] Midterm Survivorship and Clinical Outcomes in Fresh Osteochondral Allograft Transplantation for the Treatment of Large Bipolar Lesions of the Knee. (2025). https://doi.org/10.1177/03635465241313139 https://doi.org/10.1177/03635465241313139
5. [5] Mid-term failure rates, timing, and mechanisms for osteochondral allograft transplantation in the knee. (2025). https://doi.org/10.1016/j.jor.2025.03.040 https://doi.org/10.1016/j.jor.2025.03.040